or Try an Advanced Search...

    Technical Analysis for ATX - Amplia Therapeutics Limited

    Grade Last Price % Change Price Change
    D 0.090 0.00% 0.000
    ATX closed unchanged on Thursday, November 21, 2024, on 16 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ATX trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 200 DMA Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    200 DMA Support Bullish -5.26%
    Narrow Range Bar Range Contraction -5.26%
    Earnings Movers Other -5.26%
    Older End-of-Day Signals for ATX ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 200 DMA about 8 hours ago
    200 DMA Resistance about 12 hours ago
    Up 2% about 12 hours ago
    Up 3% about 12 hours ago
    Up 1% about 13 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ATX Chart by TradingView
    Basic chart:

    Profile

    Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3). FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Health Medicine Pharmaceutical Disease Diseases Cancer Drugs Tumor Oncology Chemotherapy Tumors Chronic Disease Fibrosis Ovarian Cancer Chronic Diseases Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis

    Is ATX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 30 Amplia Therapeutics Stock Down 10.0% But Insiders Still In AU$763k Profit
    Sep 19 FDA FAST TRACK DESIGNATION FOR NARMAFOTINIB IN ADVANCED PANCREATIC CANCER
    May 23 Allan Moss Buys 40% More Amplia Therapeutics Shares
    See more ATX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.18
    52 Week Low 0.055
    Average Volume 1,011,399
    200-Day Moving Average 0.093
    50-Day Moving Average 0.129
    20-Day Moving Average 0.109
    10-Day Moving Average 0.095
    Average True Range 0.008
    RSI (14) 32.43
    ADX 32.43
    +DI 15.099
    -DI 35.289
    Chandelier Exit (Long, 3 ATRs) 0.135
    Chandelier Exit (Short, 3 ATRs) 0.111
    Upper Bollinger Bands 0.150
    Lower Bollinger Band 0.068
    Percent B (%b) 0.27
    BandWidth 75.963
    MACD Line -0.012
    MACD Signal Line -0.011
    MACD Histogram -0.0009
    Fundamentals Value
    Market Cap 9.68 Million
    Num Shares 108 Million
    EPS -0.05
    Price-to-Earnings (P/E) Ratio -1.91
    Price-to-Sales 0.00
    Price-to-Book 2.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.095
    Resistance 3 (R3) 0.095 0.094 0.094
    Resistance 2 (R2) 0.094 0.093 0.094 0.093
    Resistance 1 (R1) 0.092 0.092 0.092 0.092 0.093
    Pivot Point 0.091 0.091 0.091 0.091 0.091
    Support 1 (S1) 0.089 0.090 0.089 0.089 0.087
    Support 2 (S2) 0.088 0.089 0.088 0.087
    Support 3 (S3) 0.086 0.088 0.086
    Support 4 (S4) 0.086